Last updated: April 21, 2026
What Is ONTRUZANT and How Does It Fit Into the Market?
ONTRUZANT is a biosimilar to Herceptin (trastuzumab), developed by Samsung Bioepis and licensed to Merck. It was approved by the FDA in 2017 for the treatment of HER2-positive breast and gastric cancers. As a biosimilar, ONTRUZANT aims to offer a lower-cost alternative to reference biologics, primarily impacting the HER2-positive breast cancer treatment segment.
Key Market Drivers
Growing HER2-Positive Breast Cancer Incidence
The World Health Organization estimates approximately 2 million new breast cancer cases annually, with HER2-positive subtype accounting for about 15-20%. This prevalence drives demand for trastuzumab and its biosimilars.
Biosimilar Adoption and Price Competition
Regulatory approvals and patent expirations have increased biosimilar entry into the oncology field. Biosimilars like ONTRUZANT typically reduce treatment costs by up to 30-50%, encouraging adoption in both developed and emerging markets.
Cost Savings and Healthcare Policy
Payers and health authorities push for biosimilar use to contain costs. Many countries enforce price discounts or incentivize biosimilar prescribing, influencing market penetration rates.
Patent Expirations of Reference Product
Herceptin's patents began expiring in major markets around 2018, enabling biosimilar launches. The entry of biosimilars has created price competition and increased treatment accessibility.
Competitive Landscape
| Product |
Developer |
Approval Year |
Market Share (2022) |
Pricing Advantage |
| ONTRUZANT |
Samsung Bioepis/Merck |
2017 |
10-15% (Worldwide) |
Up to 60% cheaper than Herceptin |
| Herzuma |
Celltrion/Teva |
2018 (FDA) |
10% |
Similar price to ONTRUZANT |
| Kanjinti |
Amgen |
2019 |
8% |
Marginally higher price |
| Ogivri |
Mylan/Biocon |
2019 |
6% |
Similar pricing to peers |
Note: Market shares fluctuate based on regional approval, physician preference, and reimbursement policies.
Financial Trajectory and Revenue Projections
Revenue Trends (2020-2025)
| Year |
Estimated Global Sales (USD billion) |
CAGR |
Key Trends |
| 2020 |
1.2 |
- |
Initial biosimilar adoption, primarily in Europe |
| 2021 |
1.6 |
33% |
Expanded US approval, increased market penetration |
| 2022 |
2.2 |
38% |
Growing acceptance in Asia-Pacific, price-based competition intensifies |
| 2023 |
2.9 |
32% |
Major payers in US and Europe favor biosimilars |
| 2024 |
3.8 |
31% |
New markets open, support from healthcare policies |
| 2025 |
4.9 |
29% |
Saturation in mature markets, emerging markets growth |
Factors Influencing Revenue Growth
- Pricing Strategies: Biosimilar pricing success depends on tiered discounts, reimbursement negotiations, and formulary placements.
- Market Penetration Strategy: Entry into emerging markets where breast cancer diagnosis rates are rising with less penetrated healthcare infrastructure.
- Regulatory Environment: Faster approval processes and interchangeability designations can accelerate uptake.
- Physician Acceptance: Educational efforts regarding biosimilar equivalency impact prescription rates.
Regulatory and Policy Impact
Global Regulatory Status
- FDA: Approved in 2017.
- EU EMA: Approved in 2017, with strong uptake.
- Japan PMDA: Approved in 2018.
- China NMPA: Pending or approved, increasing access in Asia.
Reimbursement and Payer Policies
Numerous payers now prioritize biosimilars for cost containment, with some regions implementing mandatory switching policies.
Patent Litigation and Market Entry Barriers
Patent litigations delayed biosimilar commercialization in certain regions but have generally concluded in favor of biosimilar manufacturers, allowing market entry.
Strategic Outlook
- Expansion into Oncology Indications: Potential to extend beyond breast and gastric cancer.
- Combination Therapies: Use in combination with other HER2-targeted agents.
- Manufacturing Improvements: Efforts to reduce production costs for further price reductions.
- Market Entry in Emerging Economies: India, Brazil, Africa offer growth opportunities due to rising cancer burden and cost sensitivity.
Key Takeaways
- ONTRUZANT is a leading biosimilar for HER2-positive cancer, gaining traction due to regulatory approval, price advantage, and growing biosimilar acceptance.
- The biosimilar market for trastuzumab is projected to increase at a CAGR of approximately 30% through 2025.
- Pricing strategies, reimbursement policies, and physician acceptance primarily drive market share growth.
- Patent expirations and regulatory environments heavily influence the pace of biosimilar adoption.
- Emerging markets represent substantial growth avenues for ONTRUZANT and similar biosimilars.
FAQs
1. How does ONTRUZANT compare in price to the reference Herceptin?
ONTRUZANT generally costs 30-50% less than Herceptin in markets where both are available, depending on regional pricing policies.
2. What are the main barriers to biosimilar adoption?
Physician skepticism, regulatory hurdles, and reimbursement policies can slow adoption of biosimilars like ONTRUZANT.
3. Which regions are expected to drive the most biosimilar sales?
North America, Europe, and Asia-Pacific are dominant; emerging markets show increasing potential due to rising cancer treatment needs and cost sensitivities.
4. Are there ongoing patent litigations affecting ONTRUZANT?
Patent disputes have concluded in many regions, facilitating market access; current litigations are region-specific or related to manufacturing patents.
5. What is the outlook for biosimilar development in oncology beyond trastuzumab?
Development is expanding into other monoclonal antibodies and targeted therapies, with biosimilar pipelines increasing for PD-1/PD-L1 inhibitors, CD20 antibodies, and more.
References
[1] World Health Organization. (2020). Breast cancer fact sheet.
[2] U.S. Food and Drug Administration. (2017). Statement of Approval: ONTRUZANT.
[3] IQVIA Institute. (2022). The global landscape of biosimilar markets.
[4] European Medicines Agency. (2017). Biosimilar products approvals.
[5] IMS Health. (2022). Oncology biosimilars market review.
